Based in New York City, New York, Ventrus Biosciences, Inc. (VTUS), is a development stage specialty pharmaceutical company focused on late stage drugs for gastrointestinal disorders. The 40M market cap company is developing two product candidates:
- Diltiazem cream (VEN 307), a topical treatment for the relief of pain associated with anal fissures; and
- Phenylephrine gel (VEN 308) for the treatment of fecal incontinence associated with ileal pouch anal anastomosis.
Many investors gave up on Ventrus after the company's lead product, iferanserin (VEN 309), a new topical treatment of hemorrhoids failed a Phase 3 trial. There were high hopes that the drug would be a blockbuster for Ventrus because there are...
Only subscribers can access this article, which is part of the PRO research library covering 3,618 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: